Conflict of interest disclosures: W. Frank Peacock—scientific advisory board at Abbott, Beckman-Coulter, Biosite, Inverness, and Response Biomedical; research grants from Abbott, BRAHMS, Biosite, and Inverness. Richard M. Nowak—research grants from BRAHMS. Robert Christenson—scientific advisory board at Siemens, Biosite, Inverness, Ortho Clinical Diagnostics, and Response Biomedical; research grants from Biosite, Inverness, Siemens, Roche, and BRAHMS. Salvatore DiSomma—consultant for Biosite; research grants from BRAHMS. Sean Xavier Neath—no conflicts of interest. Oliver Hartmann—statistical consultant and employee of BRAHMS GmbH (manufacturer of the MR-proANP, copeptin, and MR-proADM assays). Christian Mueller—scientific advisory board at Abbott and BRAHMS; research grants from Abbott, BRAHMS, Biosite, and Nanosphere. Piotr Ponikowski—no conflict of interest. Martin Mockel—research grants from BRAHMS. Christopher Hogan—no conflicts of interest. Alan H.B. Wu—research grants from BRAHMS and Response Biomedical; scientific advisory board at Beckman, Abbott, and Inverness. Mark Richards—honoraria and consultancy for Inverness, BRAHMs, and Roche Diagnostics. Gerasimos S. Filippatos—research grant from BRAHMS. Inder Anand—research grant from BRAHMS. Leong L. Ng—research grants from BRAHMS. Lori B. Daniels—research grants from Biosite and Roche. Nils Morgenthaler—employee of BRAHMS GmbH (manufacturer of the MR-proANP, Copeptin and MR-proADM assays). Stefan D. Anker—research grants from BRAHMS; honoraria from Abbott and Biosite; consultant for BRAHMS, Inverness, and Abbott. Alan S. Maisel—research grants from Roche, Biosite, and Bayer; consultant for Biosite.
Short-term Mortality Risk in Emergency Department Acute Heart Failure
Article first published online: 11 SEP 2011
© 2011 by the Society for Academic Emergency Medicine
Academic Emergency Medicine
Volume 18, Issue 9, pages 947–958, September 2011
How to Cite
Frank Peacock, W., Nowak, R., Christenson, R., DiSomma, S., Neath, S. X., Hartmann, O., Mueller, C., Ponikowski, P., Möckel, M., Hogan, C., Wu, A. H. B., Richards, M., Filippatos, G. S., Anand, I., Ng, L. L., Daniels, L. B., Morgenthaler, N., Anker, S. D. and Maisel, A. S. (2011), Short-term Mortality Risk in Emergency Department Acute Heart Failure. Academic Emergency Medicine, 18: 947–958. doi: 10.1111/j.1553-2712.2011.01150.x
Bach Trial Registration. ClinicalTrials.gov Identifier: NCT00537628.
Supervising Editor: Stephen Smith, MD.
- Issue published online: 11 SEP 2011
- Article first published online: 11 SEP 2011
- Received December 15, 2010; revisions received February 6 and February 24, 2011; accepted March 4, 2011.
- 7ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008; 29:2388–442., , , et al.
- 8Preamble. Society of Chest Pain Centers Recommendations for the Evaluation and Management of the Observation Stay Acute Heart Failure Patient. Crit Pathways in Cardiol. 2008; 7:88–9., .
- 16Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail. 2007; 13:42–9., , , et al.